Sponsored by
Good news from IN8bio! They recently announced positive trends from their Phase 1/2 trial of gamma-delta T cell therapy in newly diagnosed glioblastoma. Patients treated with repeated doses had a median progression-free survival of 13 months, nearly double that seen with standard of care. Median overall survival has not been reached, but it exceeds 17 months so far. Several treated patients remain progression-free beyond two years, and the therapy has been well tolerated, with no serious treatment-related toxicities reported.